This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
DUODOPA (levodopa/carbidopa intestinal gel)
DUODOPA
(levodopa/carbidopa intestinal gel)
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion)
PRODUODOPA
(foslevodopa/foscarbidopa solution for infusion)
A look at Complex/Advanced Parkinson's disease
DUODOPA (levodopa/carbidopa intestinal gel) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.2
Levodopa may activate malignant melanoma, so PRODUODOPA and DUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.1,2
The progressive stages of Parkinson’s
Pinpointing the progression of a patient’s Parkinson’s disease (PD) to a more Complex/Advanced stage is difficult, but a key indicator is when symptoms become more complex and start affecting daily life.3 As their condition advances, people with PD commonly develop motor response fluctuations and/or dyskinesias.4,5
Worsening gastric emptying over time in patients with PD can result in erratic absorption of oral regimens9
Gastrointestinal dysfunction, with erratic gastric emptying worsening over the years, can be a common cause of poor absorption of oral regimens in patients with PD.9
Oral regimens can become increasingly complex as PD progresses10 and complex treatment may be associated with non-adherence.11
Worsening gastric emptying over time in patients with PD can result in erratic absorption of oral regimens9
Gastrointestinal dysfunction, with erratic gastric emptying worsening over the years, can be a common cause of poor absorption of oral regimens in patients with PD.9
Oral regimens can become increasingly complex as PD progresses10 and complex treatment may be associated with non-adherence.11
of patients may experience a narrowing of the therapeutic window due to continuous neurodegeneration within 5 years of starting oral treatment, making it difficult to deliver an optimal dose to control symptoms without triggering treatment-related dyskinesia9
Learn more about patient burden
Stay connected
Keep up to date with future resources, support, and guidance to help you manage your patients with PD by filling out your details below and joining the mailing list.
Please only fill out your details if you are a UK registered healthcare professional.
1. DUODOPA (levodopa/carbidopa intestinal gel) SmPC.
2. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) SmPC.
3. Parkinson’s UK. Advanced Parkinson’s. Available at: https://www.parkinsons.org.uk/information-and-support/advanced-parkinsons. Accessed December 2024.
4. Odin P, et al. Parkinsonism Relat Disord 2015; 21: 1133–44.
5. Worth PF. Pract Neurol 2013; 13: 140–52.
6. Antonini A, et al. Curr Med Res Opin. 2018; 34: 2063–73.
7. Nyholm D. Parkinsonism Relat Disord. 2007; 13 Suppl: S13–7.
8. Olanow CW, et al. Nat Clin Pract Neurol. 2006; 2(7): 382–92.
9.Varanese S, et al. Parkinsons Dis. 2011; 2010: 480260.
10. Fleisher JE, Stern MB. Curr Neurol Neurosci Rep. 2013; 13(10): 382.
11. Grosset KA, et al. Mov Disord. 2005; 20(11): 1502–7.
By clicking the links above you will leave the AbbVie Pro website and be taken to the eMC PI portal website
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-PRODD-240194. Date of preparation: December 2024
